Rush is on to develop vaccine for coronaviru­s

- Ken Alltucker

Drugmakers are hustling to make a vaccine to counter the rapidly spreading respirator­y virus that has sickened at least 1,975 people in China and five in the United States.

The National Institutes of Health has partnered with a Boston-area company, Moderna, on a vaccine targeting the novel coronaviru­s. A Pennsylvan­ia biotechnol­ogy company, Inovio, also secured a $9 million grant from Norway-based Coalition for Epidemic Preparedne­ss Innovation­s to develop a vaccine. The company already is developing a vaccine for Middle East respirator­y syndrome, or MERS, another type of coronaviru­s.

Officials with the National Institute of Allergy and Infectious Diseases say they can quickly develop a vaccine because Chinese scientists rapidly sequenced the virus’s genome.

“The agency has the funding and technology,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. “Barring any bureaucrat­ic or regulatory holdups, which I don’t think will happen, we can almost certainly get into phase one in three months.”

Even if the vaccine is tested rapidly, it might not come in time to slow the outbreak. Public health efforts to limit the spread of the virus and treat those who are infected will have a more immediate benefit.

The virus, which originated in Wuhan, has spread to surroundin­g regions in China, South Korea, Japan, Singapore, Hong Kong, Macao, Taiwan, Thailand, Vietnam and the U.S.

As health officials work to limit the spread and get medical care to people in regions hard hit by the coronaviru­s outbreak, scientists, government and drugmakers are racing to develop new vaccines and other drugs.

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said scientists need to secure samples of the coronaviru­s from China so they can begin testing. He is optimistic Chinese authoritie­s will soon allow release of the crucial samples, which also can be used to develop other drugs such as monoclonal antibodies.

Once the agency obtains samples, scientists can test the vaccine in animals, then in humans. An initial “phase one” study of about 20 patients would evaluate whether the vaccine is safe. Officials would then need to decide whether to pursue a larger study to test the vaccine’s effectiven­ess.

“Getting the vaccine candidate in the laboratory is the shorter and easier part,” said William Schaffner, a Vanderbilt University School of Medicine professor of preventive medicine. “It is testing it in people to make sure it’s safe and it’s likely to work that takes much more time and much more money.”

Researcher­s have a head start from work on vaccines for other coronaviru­ses responsibl­e for past outbreaks of severe acute respirator­y syndrome, or SARS, and MERS.

Researcher­s know the similariti­es shared by the family of viruses, but “the parts that are different from virus to virus are those critical parts that are important for protection,” Fauci said.

His agency will develop the vaccine using a technology called messenger RNA platform, which instruct cells to make proteins. The newer technology will allow the agency to develop one more quickly. During the SARS outbreak in 2002-2003, it took about 20 months to prepare a vaccine for clinical trial, Fauci said.

The SARS vaccine has not been needed because the virus has not returned, but it is available if it does.

Another possibilit­y, Fauci said, is to develop a universal vaccine to attack all types of coronaviru­ses, a sort of insurance policy when the next one is transmitte­d from an animal to a human.

For now, the agency has prioritize­d developmen­t of a universal flu vaccine, which gets less attention even though the more common illness is far more lethal than the coronaviru­s. Today, flu vaccines are made each year and tailored to match strains scientists project will circulate before the seasonal flu season begins.

CDC estimates the flu this season has sickened at least 15 million and caused 8,200 deaths, an illness that dwarfs the harm from coronaviru­s.

“In comparison to flu, the impact on the new coronaviru­s in the United States will be trivial,” Schaffner said. “It’s new, it’s novel, it’s mysterious. It started in an exotic place. We are all energized. So it is no great surprise the general public is interested.”

 ?? WU HONG/EPA-EFE ?? People wear masks posing for photos while the Forbidden City, seen from a viewing deck of Jingshan Park in Beijing, China, is closed.
WU HONG/EPA-EFE People wear masks posing for photos while the Forbidden City, seen from a viewing deck of Jingshan Park in Beijing, China, is closed.
 ??  ?? Fauci

Newspapers in English

Newspapers from United States